Figures & data
Figure 1. PMTA of uterine myoma was performed in a patient and the microwave antenna (A) and thermocouple needle (T) were inserted percutaneously into the target.
![Figure 1. PMTA of uterine myoma was performed in a patient and the microwave antenna (A) and thermocouple needle (T) were inserted percutaneously into the target.](/cms/asset/fde85eee-66e3-42c8-beea-1dd51c257fc5/ihyt_a_562872_f0001_b.gif)
Figure 2. (A) The ultrasound image of 2D grey-scale of uterus myoma at 10 s after MW therapy. Echo enhancement began around the antennas. (B) Ultrasound image of 2D grey-scale of uterus myoma at 70 s after MW therapy. The area of echogenicity is noted to be enlarged. (C) Ultrasound image of 2D grey-scale of uterus myoma at the end of ablation. The whole myoma is obscured due to echoes.
![Figure 2. (A) The ultrasound image of 2D grey-scale of uterus myoma at 10 s after MW therapy. Echo enhancement began around the antennas. (B) Ultrasound image of 2D grey-scale of uterus myoma at 70 s after MW therapy. The area of echogenicity is noted to be enlarged. (C) Ultrasound image of 2D grey-scale of uterus myoma at the end of ablation. The whole myoma is obscured due to echoes.](/cms/asset/3dc62771-2b14-4f45-be67-6b14252f8591/ihyt_a_562872_f0002_b.gif)
Figure 3. (A) CDFI of myoma before ablation shows the myoma with hyperperfusion. (B) CDFI of ablated myoma at the end of ablation. No residual colour Doppler is demonstrated.
![Figure 3. (A) CDFI of myoma before ablation shows the myoma with hyperperfusion. (B) CDFI of ablated myoma at the end of ablation. No residual colour Doppler is demonstrated.](/cms/asset/6cceaef0-0b93-449c-837f-d869038c2c90/ihyt_a_562872_f0003_b.gif)
Figure 4. (A) Contrast enhanced ultrasound (ceUS) image of myoma before ablation. The fibroid was obviously enhanced. (B) CeUS of myoma 1 day following ablation showing no ultrasound contrast enhancement in the myoma.
![Figure 4. (A) Contrast enhanced ultrasound (ceUS) image of myoma before ablation. The fibroid was obviously enhanced. (B) CeUS of myoma 1 day following ablation showing no ultrasound contrast enhancement in the myoma.](/cms/asset/5cc95558-b57c-411d-82e9-e30af21f5d11/ihyt_a_562872_f0004_b.gif)
Figure 5. (A) CeMRI picture of myoma before ablation shows the fibroid was obviously enhanced. (B) Sagittal ceMRI of the pelvis following PMTA of a fibroid in the posterior wall of uterus. No enhancement is seen in the fibroid.
![Figure 5. (A) CeMRI picture of myoma before ablation shows the fibroid was obviously enhanced. (B) Sagittal ceMRI of the pelvis following PMTA of a fibroid in the posterior wall of uterus. No enhancement is seen in the fibroid.](/cms/asset/b7bdc549-1725-4270-bd85-76d3b9c5205f/ihyt_a_562872_f0005_b.gif)
Table I. Fibroid volume and volume reduction at baseline, 3, 6, 9 and 12 months follow up.
Table II. Patient symptoms after ablation.